Mark Gergen, Poseida CEO

Po­sei­da lines up an­oth­er al­lo­gene­ic CAR-T part­ner, al­ly­ing with Astel­las on sol­id tu­mors

Astel­las will buy about 8.8% of Po­sei­da Ther­a­peu­tics for $25 mil­lion, and match that with a one-time pay­ment for right of first re­fusal to li­cense the biotech’s clin­i­cal-stage cell ther­a­py for sol­id tu­mors, the com­pa­nies said Mon­day morn­ing.

Along­side the $50 mil­lion, Astel­las nabs a board ob­serv­er seat and can sit in on Po­sei­da’s sci­en­tif­ic ad­vi­so­ry meet­ings.

The deal fol­lows an­oth­er al­lo­gene­ic CAR-T pact that the San Diego-based biotech inked with Roche last Au­gust. That tie-up fo­cused on hema­to­log­i­cal ma­lig­nan­cies, which in­clud­ed $110 mil­lion up­front and an equal amount in near-term cash, for work on mul­ti­ple as­sets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.